ProCE Banner Activity

Le nostre considerazioni riguardo alle implicazioni dei nuovi dati su LLC e MCL emersi dallASCO 2022

Clinical Thought
In questo approfondimento, 2 esperti discutono sui recenti e importanti risultati degli studi clinici presentati all ASCO 2022, che potrebbero avere un impatto sul trattamento della leucemia linfocitica cronica e del linfoma a cellule mantellari.

Released: July 12, 2022

Expiration: July 11, 2023

Share

Faculty

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Lilly

Faculty Disclosure

Primary Author

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD: consultant: AbbVie, AcertaPharma, ADCT Therapeutics, AstraZeneca, Celegene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: consultant: AbbVie, Acerta/AstraZeneca, Adaptive, AZ, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.